Medistim Beheer

Beheer criteriumcontroles 2/4

De CEO Medistim's is Kari Krogstad, benoemd in Sep2009, heeft een ambtstermijn van 15.08 jaar. De totale jaarlijkse vergoeding van { bedraagt NOK 7.21M, bestaande uit 42% salaris en 58% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.39% van de aandelen van het bedrijf, ter waarde NOK 12.35M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 9.8 jaar en 1.8 jaar.

Belangrijke informatie

Kari Krogstad

Algemeen directeur

NOK 7.2m

Totale compensatie

Percentage CEO-salaris	42.0%
Dienstverband CEO	15.1yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	9.8yrs
Gemiddelde ambtstermijn bestuur	1.8yrs

Recente managementupdates

Recent updates

Medistim ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 19

Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Is Medistim ASA's(OB:MEDI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Mar 19

Medistim ASA (OB:MEDI) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 02

Here's What You Should Know About Medistim ASA's (OB:MEDI) 1.1% Dividend Yield

Feb 19

A Look Into Medistim's (OB:MEDI) Impressive Returns On Capital

Jan 21

Have Insiders Been Selling Medistim ASA (OB:MEDI) Shares?

Dec 27

Medistim (OB:MEDI) Has Rewarded Shareholders With An Exceptional 375% Total Return On Their Investment

Dec 10

Could The Market Be Wrong About Medistim ASA (OB:MEDI) Given Its Attractive Financial Prospects?

Nov 23

Analyse CEO-vergoeding

Hoe is Kari Krogstad's beloning veranderd ten opzichte van Medistim's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	NOK 104m
Mar 31 2024	n/a	n/a	NOK 103m
Dec 31 2023	NOK 7m	NOK 3m	NOK 104m
Sep 30 2023	n/a	n/a	NOK 117m
Jun 30 2023	n/a	n/a	NOK 116m
Mar 31 2023	n/a	n/a	NOK 116m
Dec 31 2022	NOK 9m	NOK 3m	NOK 114m
Sep 30 2022	n/a	n/a	NOK 98m
Jun 30 2022	n/a	n/a	NOK 92m
Mar 31 2022	n/a	n/a	NOK 93m
Dec 31 2021	NOK 6m	NOK 3m	NOK 91m
Sep 30 2021	n/a	n/a	NOK 88m
Jun 30 2021	n/a	n/a	NOK 84m
Mar 31 2021	n/a	n/a	NOK 70m
Dec 31 2020	NOK 6m	NOK 3m	NOK 69m
Sep 30 2020	n/a	n/a	NOK 71m
Jun 30 2020	n/a	n/a	NOK 74m
Mar 31 2020	n/a	n/a	NOK 75m
Dec 31 2019	NOK 4m	NOK 3m	NOK 70m
Sep 30 2019	n/a	n/a	NOK 79m
Jun 30 2019	n/a	n/a	NOK 73m
Mar 31 2019	n/a	n/a	NOK 64m
Dec 31 2018	NOK 4m	NOK 2m	NOK 57m
Sep 30 2018	n/a	n/a	NOK 46m
Jun 30 2018	n/a	n/a	NOK 48m
Mar 31 2018	n/a	n/a	NOK 45m
Dec 31 2017	NOK 4m	NOK 2m	NOK 48m

Compensatie versus markt: De totale vergoeding ($USD 678.93K ) Kari } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Norwegian markt ($USD 481.15K ).

Compensatie versus inkomsten: De vergoeding van Kari is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Kari Krogstad (60 yo)

15.1yrs

Tenure

NOK 7,205,702

Compensatie

Ms. Kari Eian Krogstad serves as Independent Director at Vistin Pharma ASA since June 24, a2020. She has been the Chief Executive Officer of Medistim ASA since September 1, 2009 and serves as its President...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kari Krogstad	CEO & President	15.1yrs	NOK 7.21m	0.39% NOK 12.0m
Thomas Jakobsen	Chief Financial Officer	no data	NOK 2.77m	0.17% NOK 5.2m
Helge Borslid	Vice President of Operations	no data	NOK 1.67m	geen gegevens
Hæge Johanne Wetterhus	Vice President of Marketing	14.2yrs	NOK 1.87m	0.0087% NOK 270.6k
Hakon Grothe	Chief Innovation Officer	5.5yrs	NOK 1.91m	0.043% NOK 1.3m
Ole Eiksund	Chief Business Development Officer	2.5yrs	NOK 1.68m	0.032% NOK 998.2k
Mike Farbelow	President of Medistim USA Inc	no data	NOK 3.63m	geen gegevens
Roger Morberg	Vice President of Sales - APAC	no data	NOK 2.55m	0.089% NOK 2.8m
Stephanie Stenhagen	Vice President of Sales EMEA	no data	NOK 1.79m	0.015% NOK 473.2k
Ole Robsrud	Managing Director of Medistim Norge AS	no data	NOK 1.83m	0.019% NOK 585.0k

9.8yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MEDI is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Oyvin Broymer	Chairman	24.8yrs	NOK 495.00k	geen gegevens
Anna Ahlberg	Independent Director	1.5yrs	geen gegevens	geen gegevens
Jon Hoem	Independent Director	1.8yrs	geen gegevens	geen gegevens
Ole Dahlberg	Independent Director	1.5yrs	geen gegevens	geen gegevens
Tove Raanes	Independent Director	10.8yrs	NOK 300.00k	geen gegevens
Peder Strand	Director	no data	geen gegevens	geen gegevens
Gry Dahle	Director	no data	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MEDI wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.

Medistim Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Medistim ASA Announces Board Changes

CEO & President recently bought kr1.9m worth of stock

CEO & President recently sold kr10.0m worth of stock

Less than half of directors are independent

Independent Director recently bought kr301k worth of stock

Independent Director recently bought kr104k worth of stock

Recent updates

Now 20% overvalued after recent price rise

Medistim ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: Revenues exceed analyst expectations

Now 6.6% overvalued

Now 26% overvalued after recent price rise

Now 20% overvalued

Medistim ASA Approves Dividend for the Year 2023, Payable on May 6, 2024

Medistim ASA Proposes Dividend

Medistim ASA Announces Board Changes

Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings released: EPS: kr5.68 (vs kr6.25 in FY 2022)

CEO & President recently bought kr1.9m worth of stock

Medistim ASA to Report Q1, 2024 Results on Apr 25, 2024

One Medistim ASA (OB:MEDI) Analyst Has Been Cutting Their Forecasts

Price target decreased by 10% to kr260

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: kr1.80 (vs kr1.82 in 2Q 2022)

CEO & President recently sold kr10.0m worth of stock

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr1.41 (vs kr1.30 in 1Q 2022)

Upcoming dividend of kr4.50 per share at 1.6% yield

Independent Director recently bought kr301k worth of stock

Consensus EPS estimates increase by 23%

Full year 2022 earnings released: EPS: kr6.25 (vs kr4.99 in FY 2021)

Danske Bank A/S acquired a 5% stake in Medistim ASA.

Medistim ASA to Report First Half, 2023 Results on Aug 31, 2023

What Does Medistim ASA's (OB:MEDI) Share Price Indicate?

Third quarter 2022 earnings: Revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Should You Be Adding Medistim (OB:MEDI) To Your Watchlist Today?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target decreased to kr300

A Look At The Intrinsic Value Of Medistim ASA (OB:MEDI)

Investor sentiment improved over the past week

Consensus EPS estimates increase by 12%

First quarter 2022 earnings: EPS misses analyst expectations

Upcoming dividend of kr3.75 per share

Medistim (OB:MEDI) Is Increasing Its Dividend To kr3.75

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Medistim ASA Proposes Ordinary Dividend for 2021, Payable on 9 May 2022

Medistim (OB:MEDI) Is Paying Out A Larger Dividend Than Last Year

Investor sentiment deteriorated over the past week

Statutory Profit Doesn't Reflect How Good Medistim's (OB:MEDI) Earnings Are

Consensus EPS estimates fall by 20%

Medistim's (OB:MEDI) Shareholders Will Receive A Bigger Dividend Than Last Year

Independent Director recently bought kr104k worth of stock

Price target decreased to kr343

Medistim ASA Proposes Dividend

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

CEO & President recently bought kr4.4m worth of stock

Medistim (OB:MEDI) Is Reinvesting To Multiply In Value

Third quarter 2021 earnings released: EPS kr1.03 (vs kr0.79 in 3Q 2020)

Medistim (OB:MEDI) Might Become A Compounding Machine

Here's Why I Think Medistim (OB:MEDI) Might Deserve Your Attention Today

Second quarter 2021 earnings released: EPS kr1.88 (vs kr1.11 in 2Q 2020)

Chief Financial Officer recently sold kr6.6m worth of stock

Medistim ASA Announces the Launch of the Pay Per Procedure Functionality to Latest MiraQTM Platform in the US Market

Here's What Medistim's (OB:MEDI) Strong Returns On Capital Mean

First quarter 2021 earnings released: EPS kr1.20 (vs kr1.16 in 1Q 2020)

Medistim ASA Approves Dividend, Payable on May 7, 2021

Full year 2020 earnings released: EPS kr3.81 (vs kr3.87 in FY 2019)

Chairman recently sold kr179m worth of stock

Is Medistim ASA's(OB:MEDI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Medistim ASA (OB:MEDI) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target raised to kr245